A New Drug Therapy for HER2+ Breast Cancer May Be on the Horizon

TOP - Daily - Breast Cancer

Patients with HER2-positive breast cancer who develop resistance to trastuzumab may soon have an alternative therapy, according to recent findings published in Clinical Cancer Research.


This therapy involves HER2-Affitoxin, a protein that combines HER2-specific affibody molecules and a modified bacterial toxin, PE38, said Jacek Capala, PhD, DSc, an investigator at the National Cancer Institute and study investigator. Instead of interfering with the HER2 signaling pathway, as trastuzumab does, this protein uses HER2 as a means to supply a form of bacterial toxin specifically to the HER2-positive cancer cells. Upon absorption of the toxin, the cells’ production of protein is inhibited and the cells are destroyed.


Although trastuzumab may have transformed the treatment of patients with HER2-positive breast cancer, medical professionals are finding a substantial number of tumors become resistant. As a member of the medical field, have you found this to be true? Do you feel Affitoxin could potentially be an alternative treatment for HER2-positive breast cancer? Please share your thoughts, opinions, and/or experiences in the comments section below.

Related Items
Breast Cancer Year in Review Introduction
2020 Year in Review - Breast Cancer published on January 24, 2021 in Breast Cancer
Retrospective Analysis Provides Insight into Treatment-Emergent Neutropenia Among Patients with Metastatic Breast Cancer Treated with Ribociclib or Palbociclib
2020 Year in Review - Breast Cancer published on January 24, 2021 in Breast Cancer
Concurrent Use of Medications with Potential Drug–Drug Interactions: Real-World Analysis of Patients Treated with CDK4/6 Inhibitors
2020 Year in Review - Breast Cancer published on January 24, 2021 in Breast Cancer
Abemaciclib plus Fulvestrant Provides Statistically Significant Benefit as First- and Second-Line Therapy for Hormone Receptor–Positive, HER2-Negative Advanced Breast Cancer
2020 Year in Review - Breast Cancer published on January 24, 2021 in Breast Cancer
Preliminary Results from a Phase 2 Trial of Fulvestrant/Palbociclib as First-Line Therapy in Postmenopausal Women with Hormone Receptor–Positive, HER2-Negative Endocrine-Sensitive Advanced Breast Cancer
2020 Year in Review - Breast Cancer published on January 24, 2021 in Breast Cancer
Ribociclib Added to Endocrine Therapy in Patients with Hormone Receptor–Positive, HER2-Negative Advanced Breast Cancer Demonstrated Favorable Quality-of-Life Results
2020 Year in Review - Breast Cancer published on January 24, 2021 in Breast Cancer
Examining Different Sequence Effects of CDK4/6 Inhibitor Combinations on Actual Real-World Outcomes of Treatment in Patients with Hormone Receptor–Positive and HER2-Negative Metastatic Breast Cancer
2020 Year in Review - Breast Cancer published on January 24, 2021 in Breast Cancer
Benefit of Alpelisib When Combined with Fulvestrant as Demonstrated Through Biomarker Subanalysis from the SOLAR-1 Study
2020 Year in Review - Breast Cancer published on January 20, 2021 in Breast Cancer
Efficacy Outcomes of Platinum-Based Chemotherapy in Patients with Hormone Receptor–Positive, HER2-Negative Metastatic Breast Cancer
2020 Year in Review - Breast Cancer published on January 20, 2021 in Breast Cancer
Retrospectively Analyzing the Use of CDK4/6 Inhibitors to Treat Adult Female Patients with Metastatic Breast Cancer
2020 Year in Review - Breast Cancer published on January 20, 2021 in Breast Cancer
Last modified: April 15, 2021